TII
14.12.2020 10:21:12 CET | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of Advanced Technology Research Council (ATRC), today announced the formation of a board of advisors at Cryptography Research Centre (CRC). The new board of advisors comprises global experts in the field of cryptography.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201214005303/en/
The appointments follow a series of rapid announcements at Technology Innovation Institute since the first Advanced Technology Research Council board meeting in August 2020.
CRC is one of the initial seven dedicated centres at TII and it is also one of the few global centres bringing together theoretical and applied cryptographers in a research-oriented setting. The cryptographers collaborate on breakthrough research projects that lead to innovative outcomes in cryptography. Spanning fields from post quantum cryptography (PQC), lightweight cryptography, cryptanalysis, cryptographic protocols, hardware-based cryptography, confidential computing, amongst others, the distinguished board of advisors will guide efforts to develop breakthrough technologies for global impact, reinforcing the UAE’s position as a global hub for innovation and R&D.
The Board of Advisors includes: Prof Joan Daemen , Professor of Symmetric Cryptography at Radboud University in The Netherlands, who co-designed the Rijndael cipher that was selected as the Advanced Encryption Standard (AES) and is also one of the co-designers of the Keccak (SHA-3) cryptographic algorithm; Prof Lejla Batina , Professor of Hardware Cryptography at Radboud University, whose expertise is in applied cryptography and embedded systems security; Dr Guido Bertoni , CEO of Security Pattern, Italy, whose research areas include cryptographic algorithms, hardware-based cryptography, applied cryptography and embedded systems security. He is also a co-designer of the Keccak (SHA-3) cryptographic algorithm. Prof. Carlos Aguilar , Professor of ISAE SUPAERO in Toulouse University, France, a post quantum cryptographer and expert in secure cryptographic implementations and computational theory; Prof. Damien Stehlé , Professor in Computer Science at École Normale Supérieure de Lyon, France, whose focus areas are post quantum cryptography, computational theory and complex algebra; and Prof. Tim Güneysu, Professor of Security Engineering at Ruhr-University Bochum, Germany, who is an expert in secure hardware implementations, cloud cryptographic schemes and secure engineering.
CRC currently employs and collaborates with scientists in multiple crucial fields of cryptography. The experts are engaged in the full spectrum of fundamental and applied cryptography and cryptanalysis research.
Speaking on the board appointments, Dr Najwa Aaraj, Chief Researcher at CRC, said: “The success of any scientific and research-focused entity is led by its board of advisors as they support in setting the vision. By bringing together renowned experts, we are connecting global expertise in the field of cryptography.”
Dr Aaraj added: “Through the research undertaken at the Cryptography Research Centre, we are confident that Abu Dhabi and the UAE will pioneer breakthrough technologies that ensure even greater enhancements in high-priority cryptographic areas.”
TII is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The Institute has seven initial dedicated research centres in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the Institute connects an intellectual community and contributes to building an R&D ecosystem in Abu Dhabi and the UAE. The Institute reinforces Abu Dhabi and the UAE’s status as a global hub for innovation and contributes to the broader development of the knowledge-based economy.
To know more about Cryptography Research Centre (CRC):
tii.ae/cryptographytii.ae/cryptography
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005303/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
